Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 19/20 | 0.58 |
| ▸ | TACR1 | P25103 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425441 | 0.89 | NOTUM (0.60) | NPY5R | |
| SCHEMBL31572868 | 0.86 | NOTUM (0.55) | NPY5R | |
| SCHEMBL14242298 | 0.86 | NPY5R (0.56) | NPY5RTACR1 | |
| SCHEMBL13016645 | 0.85 | NPY5R (0.57) | NPY5RTACR1 | |
| SCHEMBL12153150 | 0.85 | NPY5R (0.55) | NPY5RTACR1 | |
| SCHEMBL14986299 | 0.83 | NPY5R (0.67) | NPY5RTACR1 | |
| SCHEMBL13677346 | 0.83 | P2RY1 (0.44) | NPY5R | |
| SCHEMBL12568547 | 0.82 | NPY5R (0.58) | NPY5RTACR1 | |
| SCHEMBL861460 | 0.82 | NPY5R (0.52) | NPY5R | |
| SCHEMBL38332 | 0.82 | NPY5R (0.55) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282867-A1 | INDOLINE-CONTAINING SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | UNIV QUEENSLAND (AU) | 2015-02-05 | — | — | US | disclosed |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | UNIV QUEENSLAND (AU) | 2015-02-05 | — | — | US | disclosed |
| US-8927503-B2 | Modulations of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-06 | — | — | US | disclosed |
| US-8927503-B2 | Modulations of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-06 | — | — | US | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | MSD K.K. (JP) | 2008-07-17 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20060204436-A1 | Tritiated growth hormone secretagogue mk-0677 | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | US | disclosed |
| EP-1641494-A1 | TRITIATED GROWTH HORMONE SECRETAGOGUE MK-0677 | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005000362-A1 | TRITIATED GROWTH HORMONE SECRETAGOGUE MK-0677 | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-0937076-B1 | SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2002-08-14 | — | — | EP | disclosed |
| US-5945428-A | SUBSTITUTED OXIMES FOR TREATMENT OF ASTHMA, COUGH, BRONCHOSPASM, INFLAMMATORY DISEASES, AND GASTROINTESTINAL DISORDERS | SCHERING CORPORATION (US) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | NPY5R 3939/4885TACR1 3263/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | NPY5R 3509/4885TACR1 4241/4885 |
| US-20060204436-A1 | Tritiated growth hormone secretagogue mk-0677 | GHSR, GHRHR, TRHR | NPY5R 68/4885TACR1 150/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | NPY5R 2188/4885TACR1 165/4885 |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | NPY5R 660/4885TACR1 187/4885 |
| US-20080171753-A1 | Carbamoyl-Substituted Spiro Derivative | HRH3, HRH4, HRH2 | NPY5R 75/4885TACR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.